For the past five decades, there has been little progress in the development of oral
anticoagulants, with the choices being limited to the vitamin K antagonists (VKAs). The …

Anticoagulants are recommended for the prevention and treatment of a wide variety of
thromboembolic events. Although existing anticoagulants are effective, their use is limited by …

Background: Heparins and warfarin are currently used as venous thromboembolism (VTE)
prophylaxis in surgery. Inhibition of factor (F) Xa provides a specific mechanism of …

Background: Apixaban is an oral, direct and highly selective factor Xa (FXa) inhibitor in late‐
stage clinical development for the prevention and treatment of thromboembolic diseases …

Abstract Apixaban (BMS-562247; 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)
phenyl)-4, 5, 6, 7-tetrahydro-1 H-pyrazolo [3, 4-c] pyridine-3-carboxamide), a direct inhibitor …

This chapter focuses on new antithrombotic drugs that are in phase II or III clinical testing.
Development of these new agents was prompted by limitations of existing antiplatelet …

Although results of some phase III clinical trials of new oral anticoagulants are now known, it
is important to understand the mechanisms of their actions. These new agents exert their …

Atrial fibrillation (AF) is a major risk factor for stroke. Currently, acetylsalicylic acid (a platelet
inhibitor) and vitamin K antagonists (VKAs; oral anticoagulants), including warfarin, are the …

Oral warfarin is associated with extensive food and drug interactions, and there is a need to
consider such interactions with the new oral anticoagulants (OACs) dabigatran etexilate …

Thrombosis is the underlying cause of a host of common, debilitating, and often fatal
cardiovascular disorders. Formation of thrombi in the arterial circulation can lead to acute …